Program at a Glance

  • Program at a Glance
  • August 12, 2020
  • August 13, 2020
  • August 14, 2020
Date Wednesday, August 12 Thursday, August 13 Friday, August 14
Room VISTA 1 VISTA 2 Grand Hall 1 Walker Hall 1 Walker Hall 2 VISTA 1 VISTA 2 Grand Hall 1 Walker Hall 1 Walker Hall 2 Grand Hall 2 VISTA 1 VISTA 2 Grand Hall 1 Walker Hall 1
7:30-8:00     Business Meeting (Walker Hall 1)
8:00-8:30 Registration Registration   Registration
8:30-9:00 Opening Remark (8:50-9:00) Working party Report  
9:00-10:30 [JS01]
KAI-KSH Joint Session
  [JS03]
EHA-KSH Joint Symposium I
- Basic
[SS06]
Benign Hematology
[ES03]
Multiple Myeloma
  [JS04]
EHA-KSH Joint Symposium II
[SS10]
Pediatric Disease
[SS11]
T-cell Lymphoma/
HD
 
10:30-10:45 Break Break   Break
10:45-11:45 [PL01]
Cutting Edge of Emerging Therapies
  [PL02]
Clinical Hematology Lecture
  [PL03]
Genomics in Hematologic Malignancies
 
11:45-12:45 [PS01]
Presidential Symposium
  [MS01]
MOU Countries Session
Poster Sesion   Award Ceremony & Closing
(11:45-12:30)
12:45-13:40 [LS01]
Amgen
[LS02]
Sanofi-Aventis
[LS03]
BMS
[LS04]
Kyowa Kirin
[LS05]
Takeda
[LS06]
Celgene
[LS07]
Handok
[LS08]
Roche
[LS09]
Novartis
[LS10]
Janssen
   
13:40-14:55 [AS01]
Asian Hematology Session 1
[AS02]
Asian Hematology Session 2
  Break (13:40-14:10)
Oral Session I (14:10-15:10)
Break (14:40-14:55)
14:55-16:25 [JS02]
KOGO-KSH Joint Session
- Genomics for Precision Hematology
[SS01]
Acute Lymphoblastic Leukemia
[SS02]
B-cell Lymphoma
[ES01]
Acute Myeloid Leukemia
  Break (15:10-15:25)

Oral Session II (15:25-16:25)

16:25-16:40 Break Break
16:40-18:10 [SS03]
Multiple Myeloma
[SS04]
Advances in Technology
[SS05]
Stem Cell: Biology and Therapeutic Target
[ES02]
Acute Lymphoblastic Leukemia
  [SS07]
Bone Marrow Failure Syndrome
[SS08]
Supportive Care
[SS09]
Cell Therapy /
Transplantation
[ES04]
Lymphoma
 
18:10-18:30    
18:30-20:00 Welcome Reception Gala Dinner
  • *Session Codes
    PL: Plenary Lecture    SS: Scientific Session    ES: Educational Session    JS: Joint Sympoisum    LS: Luncheon Symposium

August 12, 2020

Room VISTA 1 VISTA 2 Grand Hall 1 Walker Hall 1 Walker Hall 2
08:00-09:00 Registration
08:50-09:00 Opening
9:00-10:30 [JS01] KAI-KSH Joint Session
- Immunotherapeutics in Blood Disease
Role of PD-1 on Regulatory T Cells in Modulating Immunity during Cancer Progression
Sang-Jun Ha, Korea
Regulation of Anti-Tumor Immunity by IL-17-producing T Cells
Yeon Seok Chung, Korea
Pro-Inflammatory Cytokines in Graft-Versus-Host Disease (GVHD)
Youngwoo Jeon, Korea
Dendritic Cell-Based Therapeutic Approaches for Treatment of Multiple Myeloma
Manh-Cuong Vo, Vietnam
10:30-10:45 Coffee Break
10:45-11:45 Plenary Lecture I - Cutting Edge of Emerging Therapies  
T Cell Immunotherapy via Native and Chimeric Receptors
Helen Heslop, USA
11:45-12:45 Presidential Symposium   
The Evolution of Acute Leukemia Diagnostics and Its Place in Treatment
Elizabeth Macintyre, France
12:45-13:40 [LS01] Luncheon Symposium [LS02] Luncheon Symposium [LS03] Luncheon Symposium [LS04] Luncheon Symposium [LS05] Luncheon Symposium
13:40-14:40 [AS01] Cutting Edge Therapeutic Approaches in CML  [AS02] Updates of Hematologic Disease in Asian Population
From Korean Perspective
Young Rok Do, Korea
Management of TDT and NTDT Thalassemia in Indonesia
Tubagus Djumhana Atmakusuma, Indonesia
From Chinese Perspective
Qian Jiang, China
Hemophilia Treatment in Singapore
Tien Sim Leng, Singapore
From Japanese Perspective
Shinya Kimura, Japan
Thalassemia Treatment in Malaysia
Jameela Sathar, Malaysia
14:55-16:25 [JS02] KOGO-KSH Joint Session
- Genomics for Precision Hematology
[SS01] Acute Lymphoblastic Leukemia          [SS02] B-cell Lymphoma [ES01] Acute Myeloid Leukemia  
Transcriptional Programs Associated  with  Aggressive  Myeloma  Progression
Hae-Ock Lee, Korea
Contemporary Treatment of Pediatric Ph+ ALL
Kirk Schultz, Canada
Genomic Landscape of DLBCL
Laura Pasqualucci, USA
Classification of AML
Sang Mee Hwang, Korea
DNA Methylation Landscape and Intra-Tumor Heterogeneity in Cancer
Sun kim, Korea
Current Treatment Approaches to Newly Diagnosed Adult ALL
Daniel J. DeAngelo, USA
Immunotherapy for Hodgkin's Lymphoma
John Kuruvilla, Canada
Treatment of Children and Adolescents with AML
Hyery Kim,Korea
Clinical Application of Next-Generation Sequencing in Acute Myeloid Leukemia
Jae-Sook Ahn, Korea Challenges in the Introduction of Next-Generation Sequencing for Diagnostics of Hematologic Malignancies
Jieun Kim, Korea
Results of High Risk and Novel Subtypes of Pediatric ALL in Japan
Katsuyoshi Koh, Japan
Optimal Treatment of High Risk Aggressive B Cell Lymphoma
Lorenz Trumper, Germany
New Agents in AML
Silvia Park, Korea
16:25-16:40 Break
16:40-18:10 [SS03] Multiple Myeloma [SS04] Advances in Technology [SS05] Stem Cell:
Biology and Therapeutic Target
[ES02] Acute Lymphoblastic Leukemia  
Novel Strategies to Overcome Relapsed/Refractory Multiple Myeloma Suzanne Trudel, Canada HARMONY: A Big Data for Better Outcomes Project in Hematological Malignancies
Jesús María Hernández Rivas, Spain
Microenvironmental Control of Hematopoietic Regeneration
Lev Silberstein, USA
Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical Aspects and Implications for Clinical Interpretation
In-Suk Kim, Korea
MRD Negativity - The Foremost Important Goal of Myeloma Treatment?
Bruno Paiva, Spain
Intelligent Image-Activated Cell Sorting: Principles and Application to Hematology
Akihiro Isozaki, Japan
A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and Leukemia
Ninib Baryawno, Sweden
Optimal Therapy for Adolescents and Young Adults with Acute Lymphoblastic Leukemia-Current Perspectives
Jae Wook Lee, Korea
Primary Amyloidosis
Ki Hyun Kim, Korea
Incorporating Genetics into Clinic
Elli Papaemmanuil, USA
BCL-2 as a Stem Cell Target in AML
Daniel A. Pollyea, USA
Current Treatment Strategies for Philadelphia Chromosome-Positive Adult ALL
Han-Seung Park, Korea
18:10-18:30 Break
18:30-20:00 Welcome Reception

August 13, 2020

Room VISTA 1 VISTA 2 Grand Hall 1 Walker Hall 1 Walker Hall 2 Grand Hall 2
08:00-09:00 Registration  
9:00-10:30 [JS03] EHA-KSH Joint Symposium I
- Basic
[SS06] Benign Hematology [ES03] Multiple Myeloma    
The Evil Side of Gene Regulation in AML
TBD
Novel Treatment for ITP
Cindy Neunert, USA
Frontline Therapy for Newly Diagnosed Multiple Myeloma
Jae-Cheol Jo, Korea
   
TET Loss-of-Function in Malignant Hematopoiesis
Myunggon Ko, Korea
Clonal Evolution under IDH Inhibitor Therapy in Acute Myeloid Leukaemia
Lynn Quek, UK
Recent Understandings of Congenital Neutropenia
TBD
Treatment of Relapsed/Refractory Multiple Myeloma
Ji Hyun Lee, Korea
   
NRAS Mutant AML
Taebo Sim, Korea
Post-Transplant Thrombotic Microangiopathy
Vahid Afshar-Kharghan, USA
AL Amyloidosis: Advance in Diagnosis and Management
Youngil Koh, Korea
   
10:30-10:45 Coffee Break  
10:45-11:45 Plenary Lecture  II - Clinical Hematology Lecture        
Genetic Landscape of Lymphoma and Novel Treatment Approaches
Wyndham Hopkins Wilson, USA
11:45-12:45 [MS01] MOU Country Session 1 Poster Presentation  
Outcome of Autologous Transplant in T Cell Lymphoma: Experience of NIHBT in Vietnam
Nguyen Vu Bao Anh, Vietnam
Subcutaneous Panniculitis-like T-cell Lymphoma
Udomsak Bunworasate, Thailand
Update of Extranodal NK/T-cell Lymphoma: Treatment and Biology
Seok Jin Kim, Korea
12:45-13:40 [LS06] Luncheon Symposium [LS07] Luncheon Symposium [LS08] Luncheon Symposium [LS09] Luncheon Symposium [LS10] Luncheon Symposium  
13:40-14:10 Break
14:10-15:10 ORAL I
15:10-15:25 Break
15:25-16:25 ORAL II
16:25-16:40 Break
16:40-18:10 [SS07] Bone Marrow Failure Syndrome [SS08] Supportive Care [SS09] Cell Therapy/Transplantation [ES04] Lymphoma    
Challenges in the Diagnosis of Bone Marrow Failure Syndromes: The Role of Genetic Panels?
Ghulam J Mufti, UK
Improve Palliative Care and Outcomes in Low- and Middle-Income Countries
Scott Howard, USA
CAR T for AML: Developing AML-Specific Anti-CD33 CAR T Cells by Gene Editing
Saar Gill, USA
Primary CNS Lymphoma
Yoon Seok Choi, Korea
   
Clonal Hematopoesis in Bone Marrow Failure
Daria V. Babushok, USA
Renal Supportive Care and Palliative Care in Patients with Hematologic Diseases
Chung Hee Back, Korea
Immune Escape and Relapse after Allogeneic Hematopoietic Cell Transplantation
Luca Vago, Italy
Extranodal NK/T Cell Lymphoma
Seong Hyun Jeong, Korea
   
The Current Treatment Algorithm for Patients with Acquired Aplastic Anemia in Japan
Shinji Nakao, Japan
Vaccinations before/after Biologic Agents in Patients with Hematologic Malignancies Dong-Gun Lee, Korea Immunosenescent Characteristics of T Cells in Young Patients Following Haploidentical Hematopoietic Stem Cell Transplantation from Parental Donors
Won-Woo Lee, Korea
Recent Advances in CLL Therapy
Jieun Uhm, Korea
   
18:10-18:30  
18:30-20:00 Gala Dinner

August 14, 2020

Room VISTA 1 VISTA 2 Grand Hall 1 Walker Hall 1 Walker Hall 2
07:30-08:30 Business Meeting
08:30-09:00 Working Party Reports  
09:00-10:30 [JS04] EHA-KSH Joint Symposium II
- Clinical Translational
[SS10] Pediatric Disease [SS11] T-Cell Lymphoma /HD    
BiTing Leukemia: T Cell Recruiting Antibody Constructs for Treatment of AML
TBD
Juvenile Myelomonocytic Leukemia: Learning from Patients in a World Without Walls
Mignon Loh, USA
PD-L1 and NK/T-Cell Lymphoma
Won Seog Kim, Korea
Therapeutic Potential of Ascorbic Acid in TET2-Mutated AML
Junshik Hong, Korea
The Emerging Role of MRD in AML
Gert Ossenkoppele, The Netherlands
The Role of RAS Mutation in Relapsed ALL
Julie Irving, UK
Novel Agents for PTCL
Francine Foss, USA
MRD in AML
Byung Sik Cho, Korea
Langerhans Cell Histiocytosis 2020: New Insights and Opportunities
Carl Allen, USA
A Translational Research in Angioimmunoblastic T-Cell Lymphoma: From Genome to Bedside
Mamiko Sakata-Yanagimoto, Japan
10:30-10:45 Coffee Break    
10:45-11:45 Plenary Lecture III - Genomics in Hematologic Malignancies      
Latest Treatment Developments in Multiple Myeloma
Nikhil Munshi, USA
Genetic Alterations in Relapsed/Refractory AML: Is There Something Special?
Hyeoung-Joon Kim, Korea
11:45-12:30 Award Ceremony & Closing
ORGANIZED BY
SUPPORTED BY
Sponsored by